The world’s biggest drugmaker reported earnings of $4.4 billion that topped estimates but revenues of $16.2 billion fell short of expectations.
Continue reading Pfizer Earnings Top Estimates, Boosts Guidance
…
Pfizer’s cancer drug crizotinib was able to shrink tumors of non-small-cell lung cancer patients whose tumors carried a specific genetic mutation that fuses two genes. The early-stage study results were published in the New Eng…
Bristol-Myers Squibb, which sells blood thinner Plavix, today reported better-than-expected third quarter earnings, mainly due to cost cuts. Revenue, however, fell short of expectations, and shares are down in trading Tuesday.
…
Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK’d, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are s…
At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off…